Drug intelligence / Profile preview

3C060-DM1

Development stage: Preclinical
Lead developer: Tottori University
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

**3C060-DM1** is an experimental, fully human epithelial cell adhesion molecule-targeted antibody-drug conjugate generated by coupling the anti-EpCAM monoclonal-antibody clone 3C060 to the maytansinoid microtubule poison DM1 through an affinity peptide-based chemical conjugation method. The conjugate showed in-vitro cytotoxicity against EpCAM-expressing HCT116 human colon cancer cells, with a reported IC50 of 0.254 micrograms per mL. It is a preclinical research ADC and has no assigned INN, marketed brand, or reported clinical-trial development program. ([nature.com](https://www.nature.com/articles/s41598-023-31263-x.pdf))

Targets

TUBB (Tubulin (alpha and beta subunits))EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on 3C060-DM1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3C060-DM1.

Explore the full profile